Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
暂无分享,去创建一个
H. Earl | M. Highley | D. Cameron | J. Crown | A. Hutcheon | J. Mansi | R. Coleman | A. Jones | T. Evans | T. Perren | T. Evans | R. Leonard | A. Yellowlees | C. Gallagher | E. Foster | M. Quigley
[1] R. Laing,et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] D. Wickerham,et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. Fumoleau,et al. Original article DOI: 10.1093/annonc/mdg449 Phase , 2022 .
[4] Hans-Peter Sinn,et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Krzakowski,et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Tabei,et al. Phase II Study of Concurrent Administration of Doxorubicin and Docetaxel as First-Line Chemotherapy for Metastatic Breast Cancer , 2003, Oncology.
[7] G. Failla,et al. Doxorubicin-Docetaxel Sequential Schedule: Results of Front-Line Treatment in Advanced Breast Cancer , 2002, Oncology.
[8] J. Blohmer,et al. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. , 2002, Clinical breast cancer.
[9] Fiona J Gilbert,et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. V. D. van de Velde,et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] W. Eiermann,et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Riva,et al. Taxane/anthracycline combinations: setting a new standard in breast cancer? , 2001, The oncologist.
[13] A. Vincent-Salomon,et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer , 2000, British Journal of Cancer.
[14] G. Hortobagyi,et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] W. McCaskill-Stevens,et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] V. Diéras,et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Crown,et al. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results. , 1998, Seminars in oncology.
[19] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Howell,et al. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. , 1997, European journal of cancer.
[21] D. Wickerham,et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Ellis,et al. Primary chemotherapy for early breast cancer. , 1996, Cancer treatment reviews.
[23] P. Fumoleau,et al. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. , 1996, British Journal of Cancer.
[24] G. Bonadonna,et al. Primary chemotherapy in operable breast cancer. , 1996, Seminars in oncology.
[25] P. Fumoleau,et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] E. Eisenhauer,et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] V. Valero,et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P M Ravdin,et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Zucali,et al. Primary chemotherapy in surgically resectable breast cancer , 1995, CA: a cancer journal for clinicians.
[30] T. Powles,et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] B. Gusterson,et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] V. Semiglazov,et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] G. Calais,et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm , 1994, Cancer.
[34] M. Piccart,et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] G. Bonadonna,et al. Preoperative chemotherapy in operable breast cancer , 1993, The Lancet.
[36] Y. Bignon,et al. Neoadjuvant chemotherapy in 126 operable breast cancers. , 1992, European journal of cancer.
[37] L. Mauriac,et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] U. Chetty,et al. Primary systemic therapy for operable breast cancer. , 1991, British Journal of Cancer.
[39] A. Luini,et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. , 1990, Journal of the National Cancer Institute.
[40] C. Jacquillat,et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast‐conserving treatment of 250 patients with all stages of infiltrative breast cancer , 1990, Cancer.
[41] G. Cocconi,et al. Neoadjuvant Chemotherapy or Chemotherapy and Endocrine Therapy in Locally Advanced Breast Carcinoma: A Prospective, Randomized Study , 1990, American journal of clinical oncology.
[42] J A McKinna,et al. Primary medical therapy for operable breast cancer. , 1989, European journal of cancer & clinical oncology.
[43] G. Hortobagyi,et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy , 1988, Cancer.
[44] G. Schwartz,et al. Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast. , 1987, Archives of surgery.
[45] I. Smith,et al. Is there still a role for neoadjuvant therapy in breast cancer? , 2003, Critical reviews in oncology/hematology.
[46] G. Bonadonna,et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] I. Bleiweiss,et al. The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer. , 1998, Cancer investigation.
[48] C. Hudis,et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] B. Asselain,et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. , 1994, European journal of cancer.
[50] M. Baum,et al. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. , 1993, European journal of cancer.
[51] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.